Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

• Main Authors: Lau G.K.K., Piratvisuth T., Kang X.L., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Wan C.C., Seung W.P., Wen Y.C., Berg T., Flisiak R., McCloud P., Pluck N.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-21244447705&partnerID=40&md5=c71bc570b7ba54802a2005db69e75fc9; http://cmuir.cmu.ac.th/handle/6653943832/1900
• Institution: Chiang Mai University

BACKGROUND: Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen...